JP2006306885A5 - - Google Patents

Download PDF

Info

Publication number
JP2006306885A5
JP2006306885A5 JP2006175983A JP2006175983A JP2006306885A5 JP 2006306885 A5 JP2006306885 A5 JP 2006306885A5 JP 2006175983 A JP2006175983 A JP 2006175983A JP 2006175983 A JP2006175983 A JP 2006175983A JP 2006306885 A5 JP2006306885 A5 JP 2006306885A5
Authority
JP
Japan
Prior art keywords
amino
fluoro
ethyl
hydroxypropyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006175983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006306885A (ja
Filing date
Publication date
Priority claimed from SE9904508A external-priority patent/SE9904508D0/xx
Priority claimed from SE0003640A external-priority patent/SE0003640D0/xx
Application filed filed Critical
Publication of JP2006306885A publication Critical patent/JP2006306885A/ja
Publication of JP2006306885A5 publication Critical patent/JP2006306885A5/ja
Pending legal-status Critical Current

Links

JP2006175983A 1999-12-09 2006-06-27 新規なアミノプロピルホスフィン酸 Pending JP2006306885A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
SE0003640A SE0003640D0 (sv) 2000-10-09 2000-10-09 New compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001543550A Division JP3914435B2 (ja) 1999-12-09 2000-12-04 新規なアミノプロピルホスフィン酸

Publications (2)

Publication Number Publication Date
JP2006306885A JP2006306885A (ja) 2006-11-09
JP2006306885A5 true JP2006306885A5 (enExample) 2008-01-17

Family

ID=26655259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001543550A Expired - Fee Related JP3914435B2 (ja) 1999-12-09 2000-12-04 新規なアミノプロピルホスフィン酸
JP2006175983A Pending JP2006306885A (ja) 1999-12-09 2006-06-27 新規なアミノプロピルホスフィン酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001543550A Expired - Fee Related JP3914435B2 (ja) 1999-12-09 2000-12-04 新規なアミノプロピルホスフィン酸

Country Status (33)

Country Link
US (5) US6576626B2 (enExample)
EP (2) EP1484333A1 (enExample)
JP (2) JP3914435B2 (enExample)
KR (1) KR100689144B1 (enExample)
CN (1) CN1198832C (enExample)
AR (1) AR030541A1 (enExample)
AT (1) ATE282043T1 (enExample)
AU (1) AU780459B2 (enExample)
BR (1) BR0016253A (enExample)
CA (1) CA2397583C (enExample)
CZ (1) CZ20021983A3 (enExample)
DE (1) DE60015796T2 (enExample)
DK (1) DK1240172T3 (enExample)
EE (1) EE05067B1 (enExample)
ES (1) ES2230174T3 (enExample)
HK (1) HK1048321B (enExample)
HU (1) HUP0300301A3 (enExample)
IL (2) IL149840A0 (enExample)
IS (1) IS2231B (enExample)
MX (1) MXPA02005536A (enExample)
MY (1) MY125414A (enExample)
NO (1) NO329595B1 (enExample)
NZ (1) NZ519376A (enExample)
PL (1) PL201789B1 (enExample)
PT (1) PT1240172E (enExample)
RU (1) RU2260595C2 (enExample)
SE (1) SE9904508D0 (enExample)
SI (1) SI1240172T1 (enExample)
SK (1) SK286904B6 (enExample)
TW (1) TWI228510B (enExample)
UA (1) UA71649C2 (enExample)
WO (1) WO2001042252A1 (enExample)
ZA (1) ZA200204127B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
JP2004521898A (ja) * 2001-02-05 2004-07-22 カム、マイケル・アルバート 食道運動性疾患及び胃食道逆流性疾病の治療方法
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
BRPI0620464A2 (pt) 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
BRPI0620372A2 (pt) 2005-12-23 2011-11-08 Astrazeneca Ab composto, composição farmaceutica, e, uso de um composto
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2155762B1 (en) * 2007-05-04 2011-10-12 AstraZeneca AB Process for the synthesis of alkyl phosphinic acids by initiation of an amine and an amineoxide
CN101743011A (zh) * 2007-07-25 2010-06-16 阿斯利康(瑞典)有限公司 (3-氨基-2-氟丙基)次膦酸用于治疗非糜烂性反流病的用途
PE20091310A1 (es) * 2007-12-21 2009-09-30 Astrazeneca Ab Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a
WO2009082348A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form c of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy
EP2346885B1 (de) 2008-11-05 2013-08-28 Clariant International Ltd. Verfahren zur herstellung von monocarboxyfunktionaslisierten dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
ES2525550T3 (es) 2008-11-07 2014-12-26 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos, ésteres y sales dialquilfosfínicos mediante derivados del ácido acrílico y su uso
JP5743219B2 (ja) 2008-11-11 2015-07-01 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド アリル化合物を用いる、モノアリル官能性ジアルキルホスフィン酸、それらの塩およびエステルの製造方法およびそれらの使用
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
JP5619769B2 (ja) 2008-12-18 2014-11-05 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド アセチレンを利用したエチレンジアルキルホスフィン酸、エチレンジアルキルホスフィン酸エステル、およびエチレンジアルキルホスフィン酸塩の製造方法、およびそれらの使用
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
EP0250572A1 (en) 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
US4740332A (en) * 1986-05-12 1988-04-26 E. R. Squibb & Sons, Inc. Process for preparing phosphonous acids
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5567840A (en) 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5281747A (en) 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL98502A (en) * 1990-06-22 1998-04-05 Ciba Geigy Ag Aminoalkane phosphinic acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Similar Documents

Publication Publication Date Title
JP2012508249A5 (enExample)
JP2005533835A5 (enExample)
CA2397583A1 (en) New aminopropylphosphinic acids
DE15177166T1 (de) S1p-rezeptormodulatoren für die behandlung von multipler sklerose
RU2015111229A (ru) Кристаллические формы гидрохлорида финголимода
JP2010138190A5 (enExample)
JP2010095546A5 (enExample)
JP2009537550A5 (enExample)
JP2004529125A5 (enExample)
JP2014500861A5 (enExample)
RU2005100836A (ru) Производные пептидов, содержащие тиазепиновую группу, для лечения гиперлипемических состояний
JP2013518050A5 (enExample)
JP2014528464A5 (enExample)
JP2009504763A5 (enExample)
JP2002543202A5 (enExample)
JP2005526836A5 (enExample)
JP2012532883A5 (enExample)
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
JP2003516346A5 (enExample)
JP2006516280A5 (enExample)
JP2017512211A5 (enExample)
JP2019519593A5 (enExample)
JP2017518363A5 (enExample)
JP2007529507A5 (enExample)
JP2008520662A5 (enExample)